SCHEMBL24184530

SCHEMBL24184530

COCCn1ncc(C)c(Br)c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 10/20 0.40
▸ RAB9A P51151 6/20 0.40
▸ NPC1 O15118 5/20 0.40
▸ SMN1; SMN2 Q16637 4/20 0.40
▸ MITF O75030 3/20 0.40
▸ MAPT P10636 2/20 0.40
▸ S1PR4 O95977 1/20 0.40
▸ S1PR1 P21453 1/20 0.40
▸ HSD17B10 Q99714 5/20 0.36
▸ CYP1A2 P05177 4/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ USP2 O75604 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.35
▸ PKM P14618 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15705515 0.80 MEN1 (0.39) ALDH1A1HSD17B10CYP1A2CYP3A4USP2
SCHEMBL22363263 0.75 LRRK2 (0.41) ALDH1A1HSD17B10CYP1A2CYP3A4USP2
SCHEMBL15703047 0.73 MEN1 (0.39) ALDH1A1HSD17B10CYP1A2CYP3A4USP2
SCHEMBL26692301 0.73 MEN1 (0.39) ALDH1A1SMN1; SMN2HSD17B10CYP1A2CYP3A4
SCHEMBL978628 0.72 HTT (0.53) ALDH1A1RAB9ANPC1SMN1; SMN2MITF
SCHEMBL25755264 0.72 NPC1 (0.36) ALDH1A1RAB9ANPC1SMN1; SMN2MITF
SCHEMBL25756148 0.72 NPBWR1 (0.61) ALDH1A1SMN1; SMN2PKMHTT
SCHEMBL20786916 0.71 NPC1 (0.55) ALDH1A1RAB9ANPC1SMN1; SMN2MITF
SCHEMBL24184142 0.70 ALDH1A1 (0.41) ALDH1A1MAPTHSD17B10CYP1A2CYP3A4
SCHEMBL15705517 0.70 MEN1 (0.37) ALDH1A1SMN1; SMN2KMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348426-A1 OXOPYRROLIDINE FPR2 AGONISTS BRISTOL MYERS SQUIBB CO (US) 2023-11-02 — — US disclosed
US-20230348426-A1 OXOPYRROLIDINE FPR2 AGONISTS BRISTOL MYERS SQUIBB CO (US) 2023-11-02 — — US disclosed
CN-116034104-A Oxo-pyrrolidine FPR2 agonists 百时美施贵宝公司 2023-04-28 — — CN disclosed
WO-2022011084-A1 OXOPYRROLIDINE FPR2 AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2022-01-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348426-A1 OXOPYRROLIDINE FPR2 AGONISTS FPR1, FPR2, FPR3 ALDH1A1 3918/4885RAB9A 4398/4885NPC1 1811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback